News
5h
Live Science on MSNDementia: Facts about Alzheimer's and other forms of dementiaDementia is a group of diseases that involve having trouble with memory, thinking, reasoning and other brain functions. It is ...
11h
Medpage Today on MSNNew Guideline Backs Some Blood Tests for Alzheimer's Disease DiagnosisTORONTO -- Blood tests for Alzheimer's disease biomarkers can be used clinically -- and can replace expensive brain scans and ...
Scientists at UCSF have uncovered how certain immune cells in the brain, called microglia, can effectively digest toxic ...
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the first to market, commercial launch of two novel phospho-tau ...
11h
Clinical Trials Arena on MSNAAIC25: ALZpath’s pTau217 advances role in Alzheimer’s disease R&DALZpath’s pTau217 antibody was released in 2023 and continues to be a key focus in Alzheimer’s disease research and ...
The Alzheimer’s Association has issued its first clinical practice guideline on the use of blood tests to help diagnose ...
Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% ...
15hon MSN
Adopting intensive lifestyle changes can slow or stop progression of early-stage Alzheimer’s disease, according to a new ...
The idea that herpes infections trigger or contribute to Alzheimer's disease has been gaining favor among some scientists, ...
TORONTO -- The antiviral agent valacyclovir demonstrated no benefit in early Alzheimer's disease, the phase II VALAD trial ...
17h
Clinical Trials Arena on MSNAAIC25: Cognito neuromodulation therapy slows decline in Alzheimer’s diseaseCognito’s OVERTURE trial demonstrated significant ‘time saved’ in functional and cognitive decline at both six and 18 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results